Design of Biodegradable Nanoparticles for Oral Delivery of Doxorubicin: In vivo Pharmacokinetics and Toxicity Studies in Rats
- 2.2k Downloads
Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance.
Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats.
Nanoparticles had an average size of 185 nm, with 49% entrapment at 10% w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1–7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20%) followed by a sustained release (80%) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity.
Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.
KEY WORDSbioavailability cardiotoxicity oral delivery oxidative stress
Area under the curve
Institutional Animal Ethics Committee
Simulated gastric fluid
Simulated intestinal fluid
DK is grateful to NIPER for providing MS fellowships. Director, NIPER is acknowledged for extending the facility to conduct the work reported in here. Mr. Chandu, Research Scholar, Department of Pharmacology and Toxicology is acknowledged for the help with animal experiments.
- 6.M. D. DeMario, and M. J. Ratain. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 16:2557–2667 (1999).Google Scholar
- 8.S. K. Carter. Adriamycin—thoughts for the future. Chemother. Rep. Cancer. 63:877–883 (1975).Google Scholar
- 9.C. Young, R. F. Ozols, and C. E. Myers. The anthracycline antineoplastic drugs. New Eng. J. Med. 305:39–153 (1981).Google Scholar
- 17.J.L. Italia, D. K. Bhatt, V. Bhardwaj, K. Tikoo, and M. N. V. R. Kumar. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J. Control. Release. 119:197–206 (2007), doi: 10.1016/j.jconrel.2007.02.004.PubMedCrossRefGoogle Scholar
- 21.J. L. Italia, P. Datta, D. D. Ankola, and M. N. V. R. Kumar. Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J. Biomed. Nanotech. 4:304–312 (2008), doi: 10.1166/jbn.2008.341.CrossRefGoogle Scholar
- 25.T. Niwa, H. Takeuchi, T. Hino, N. Kunou, and Y. Kawashima. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with d,l-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method and the drug release behavior. J. Control. Release. 25:89–98 (1993), doi: 10.1016/0168-3659(93)90097-O.CrossRefGoogle Scholar